Swallowing therapy showed no clear difference in death or dependency at end of trial compared with placebo (moderate certainty).
Swallowing therapy showed no clear difference in case fatality at end of trial compared with placebo (moderate certainty).
Swallowing therapy may leads to lower proportion of participants with dysphagia at end of trial compared with placebo (low certainty).
It is very uncertain whether swallowing therapy changes adverse event: chest infection or pneumonia compared with placebo (very low certainty).
The review found no eligible studies for this question.
Blood pressure‐lowering drugs (BPLDs) probably leads to lower recurrent stroke of any type compared with placebo or no treatment (moderate certainty).
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in major vascular event (composite of non‐fatal stroke, non‐fatal… compared with placebo or no treatment (high certainty).
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in myocardial infarction compared with placebo or no treatment (high certainty).
Blood pressure‐lowering drugs (BPLDs) leads to lower vascular death compared with placebo or no treatment (high certainty).
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in death by any cause compared with placebo or no treatment (moderate certainty).
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in dementia compared with placebo or no treatment (high certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during treatment (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during compared with unfractionated heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids may leads to lower deep vein thrombosis during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in pulmonary embolism during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
Low‐molecular‐weight heparins or heparinoids showed no clear difference in symptomatic intracranial haemorrhage/haemorrhagic transformation of… compared with unfractionated heparin (low certainty).
It is very uncertain whether summary of findings: SLT changes expressive language: naming (6 months compared with no SLT (follow‐up at 6 months) (very low certainty).